CStone Strikes Oceania Deal with Arrotex for Anti-PD-L1 Antibody Sugemalimab
核心洞察
CStone Pharmaceuticals signed an exclusive commercialization agreement with Arrotex Pharmaceuticals (搜索) to bring sugemalimab to Australia and New Zealand.
Arrotex will handle regulatory submissions and commercialization across all approved and future indications, including NSCLC, gastric cancer (搜索), ESCC, and ENKTL.
CStone receives upfront and milestone payments plus profit share, marking sugemalimab's fifth international partnership covering over 60 countries.
CStone Pharmaceuticals has entered into an exclusive commercialization agreement with Arrotex Pharmaceuticals (搜索) Pty Ltd for the anti-PD-L1 (搜索) monoclonal antibody sugemalimab across Australia and New Zealand, the company announced on June 25, 2026. Arrotex, the pharmaceutical commercialization platform of DBG Health (搜索) — Australia's largest diversified healthcare group — will assume responsibility for regulatory submissions, market access, and commercialization activities in the licensed territory.
Under the terms of the agreement, CStone will receive an upfront payment and is eligible for additional regulatory and commercial milestone payments. The Suzhou-based biopharmaceutical company will supply sugemalimab to Arrotex and recognize a profit share arrangement.
Expanding a Global Footprint
This partnership represents sugemalimab's fifth international commercialization agreement, extending the drug's reach into Oceania and bringing its global commercial footprint to over 60 countries and regions across Europe, the Middle East and Africa, Latin America, and now Oceania. The deal builds on existing approvals from the European Commission (EC) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for stage III and IV non-small cell lung cancer (搜索) (NSCLC).
Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated: "This agreement with Arrotex marks another milestone in the global commercialization of sugemalimab, successfully extending its commercialization reach into the Oceania region. Australia and New Zealand are well-established pharmaceutical markets with regulatory frameworks closely aligned with those of the EU and US."
Yang emphasized that Arrotex's commercialization infrastructure and established pharmacy network position the partnership well to support the introduction of sugemalimab in these markets, noting that existing EU and UK approvals provide "a clear and efficient regulatory pathway for Australia and New Zealand."
Indications and Regulatory Pathway
Arrotex will hold exclusive commercialization rights for sugemalimab in Australia and New Zealand across all approved and future indications, subject to regulatory approval by Australia's Therapeutic Goods Administration (TGA). The indications covered include stage III and IV NSCLC, gastric cancer (搜索), esophageal squamous cell carcinoma (搜索) (ESCC), and extranodal NK/T-cell lymphoma (搜索) (ENKTL).
Dennis Bastas, Chairman and Group Chief Executive Officer of DBG Health (搜索), commented: "We are excited to be partnering with CStone to bring this innovative therapy to Australia and New Zealand. This partnership enables early commercial planning for CStone's product while bringing together two organisations with a shared commitment to improving outcomes for people affected by cancer."
Bastas added that Arrotex's "deep expertise in regulatory engagement, market access, and distribution across Australia and New Zealand — combined with CStone's strong development capabilities — positions us well to accelerate access to this important new treatment for patients across multiple indications."
Sugemalimab's Clinical Profile
Sugemalimab is a fully human, full-length anti-PD-L1 (搜索) immunoglobulin G4 (IgG4) monoclonal antibody developed using the OmniRat® transgenic animal platform, which enables the creation of fully human antibodies in a single step. This design may reduce the risk of immunogenicity and toxicity for patients.
The drug has secured approvals from the EC and MHRA for two indications: in combination with platinum-based chemotherapy for first-line treatment of metastatic NSCLC without sensitizing EGFR mutations or ALK, ROS1, or RET genomic tumor aberrations; and as monotherapy for adults with unresectable stage III NSCLC with PD-L1 (搜索) expression on ≥1% of tumor cells whose disease has not progressed following platinum-based chemoradiotherapy.
In China, the National Medical Products Administration (NMPA) has approved sugemalimab for five indications spanning first-line metastatic squamous and non-squamous NSCLC, unresectable stage III NSCLC, relapsed or refractory ENKTL, first-line ESCC, and first-line gastric or gastroesophageal junction adenocarcinoma with PD-L1 (搜索) expression CPS ≥5.
ESMO Guidelines recommend sugemalimab [I, A] for first-line treatment of both squamous and non-squamous stage IV NSCLC in combination with platinum-based chemotherapy, as well as consolidation therapy for up to 24 months in patients with stage III NSCLC who are EGFR wild-type and lack ALK or ROS1 genomic aberrations following chemoradiotherapy without disease progression.
About the Companies
CStone, founded in late 2015 and listed on the Hong Kong Stock Exchange (HKEX: 2616), focuses on oncology, immunology, inflammation, and other key disease areas. The company has launched four innovative drugs and secured 21 new drug applications covering nine indications, with a pipeline of 16 candidates featuring antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
Arrotex Pharmaceuticals (搜索), part of DBG Health (搜索), is Australia's largest and most diversified pharmaceutical company, offering an extensive range of prescription medicines across therapeutic areas.